Tesamorelin side effects from the Egrifta Phase 3 trials and monograph: injection-site reactions, arthralgia, oedema, glucose and IGF-1 signals, and why none of it transfers to research-grade vials.
Tesamorelin is a stabilised analogue of full-length growth hormone-releasing hormone, and it is the one compound in this catalogue with an approved-medicine safety record. As Egrifta, from Theratechnologies of Montréal, it holds Health Canada and FDA authorisation for excess abdominal fat in adults with HIV-associated lipodystrophy, and its product monograph tabulates adverse reactions from controlled trials in more than 800 patients. That makes this page unusual, and it makes one distinction essential. The monograph describes Egrifta, manufactured under licence and given to a defined population; research-grade tesamorelin is a different product with no safety data of its own. This page is a research reference, not advice.
The Tesamorelin profile is the reference entry; the research overview covers the mechanism and the dosage notes summarise the trial regimens.
The pivotal evidence is two randomised, double-blind, placebo-controlled Phase 3 trials in adults with HIV and abdominal fat accumulation, each 26 weeks at 2 mg subcutaneously once daily followed by a 26-week extension. The first was published by Falutz and colleagues in the New England Journal of Medicine (2007); the pooled analysis with safety-extension data appeared in the Journal of Clinical Endocrinology & Metabolism (2010) and is the source of the adverse-reaction table in the monograph.
In that pooled analysis the events more frequent on tesamorelin than placebo were injection-site erythema and pruritus, arthralgia, peripheral oedema, myalgia and paraesthesia — the recognisable signature of raised growth hormone. Hypersensitivity reactions including rash and urticaria occurred in a small percentage of patients. Discontinuation for adverse events was higher on tesamorelin than on placebo. Visceral fat fell by roughly 15 to 18 percent and returned after the drug was stopped in the extension, a durability finding rather than a safety one.
Later trials add duration, not new categories. The Massachusetts General Hospital studies — JAMA (2014) and The Lancet HIV (2019) — used the same 2 mg daily dose for 6 and 12 months in people with HIV, and the Archives of Neurology (2012) cognition trial used 1 mg daily for 20 weeks in older adults. The population in which tesamorelin has a measured adverse-event profile remains people with HIV, with one small study in healthy older adults.
Two findings deserve separation from the list above because they are the ones the labelling is built around.
Glucose. Average fasting glucose and HbA1c changed little over 26 weeks, but a proportion of patients developed impaired glucose tolerance or diabetes during treatment, and the labelling advises monitoring glucose. Growth hormone is counter-regulatory to insulin, so this is the expected direction; the trials add that it was observed in a controlled setting at the approved dose.
IGF-1. IGF-1 rose by roughly 100 µg/L on average and exceeded the upper reference range in a meaningful minority. Because IGF-1 is mitogenic, the labelling contraindicates tesamorelin in active malignancy and advises caution with any history of cancer. The trials excluded such patients, so the long-term oncological risk is unmeasured rather than known to be low — the same gap that applies to every GHRH analogue, with the difference that here it is written into an approved label.
The approved labelling records what a research-market page for any other compound could only speculate about. Tesamorelin is contraindicated in pregnancy, in active malignancy, and in anyone with a disrupted hypothalamic–pituitary axis from a tumour, surgery or radiation. The monograph also notes that tesamorelin can alter the metabolism of drugs cleared by cytochrome P450 enzymes, since GH affects hepatic enzyme expression, and advises monitoring for drugs with narrow therapeutic windows. Glucocorticoids and somatostatin analogues blunt the GH response.
Pharmacokinetically the compound is short-lived: a plasma half-life of 26 minutes in healthy adults and 38 minutes in patients with HIV, with subcutaneous bioavailability under 4 percent. The daily injection adds a pulse to the pituitary's own rhythm rather than maintaining a steady drug level, which is why the adverse-event profile resembles that of intermittent GH elevation rather than the sustained exposure seen with albumin-bound CJC-1295.
Community reports add injection-site lumps, water retention and joint stiffness — consistent with the trial list, but uncontrolled and undenominated.
Tesamorelin is a 44-residue peptide with a methionine at position 27 that is vulnerable to oxidation, and the approved product's labelling instructs immediate use after reconstitution because storage of the solution was never validated. Research-grade material follows the same chemistry: deamidated and oxidised variants are the impurities to look for on a certificate of analysis, and long peptides aggregate if agitated or stored warm. Reactions in unregulated use can trace to impurities, endotoxin or degraded material rather than the molecule; lab testing and COAs describes what each lot is tested for and the cold-chain and shelf-life guide covers storage.
Egrifta holds a Health Canada market authorisation and a DIN for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, and is a prescription drug in Canada; it has been FDA-approved since 2010. That authorisation covers the licensed product, its manufacturer, its indication and its population. The research-grade tesamorelin sold here carries no DIN and is supplied for laboratory research only. The World Anti-Doping Agency lists GHRH and its analogues under S2 and names tesamorelin explicitly; it is prohibited for tested athletes at all times.
What side effects did the tesamorelin trials report? In the pooled Phase 3 analysis (Falutz et al., 2010) the events more frequent than placebo were injection-site erythema and pruritus, arthralgia, peripheral oedema, myalgia and paraesthesia, with hypersensitivity reactions in a small minority and more discontinuations for adverse events than on placebo.
Does tesamorelin affect blood sugar? On average, little over 26 weeks, but a proportion of patients developed impaired glucose tolerance or diabetes during treatment, and the labelling advises glucose monitoring.
Why is tesamorelin contraindicated in cancer? It raises IGF-1, which is mitogenic, and IGF-1 exceeded the reference range in a meaningful minority of trial patients. Patients with malignancy were excluded from the trials, so the risk is unmeasured, and the labelling takes the cautious position.
Does the Egrifta safety data apply to research-grade tesamorelin? No. The monograph describes a licensed product manufactured under Health Canada and FDA oversight and given to people with HIV lipodystrophy. Research-grade material has not been tested in any trial and has no safety data of its own.
Is tesamorelin prohibited in sport? Yes. WADA names tesamorelin under S2, GHRH and its analogues, prohibited at all times.
Is this medical advice? No. This page summarises published trial and labelling data for laboratory reference. Research-grade tesamorelin is not Egrifta, is not for human or veterinary use, and nothing above is a safety assurance or a dosing recommendation. Health decisions belong with a qualified physician.
